

Solexa, Inc.
Form 425
January 08, 2007

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): January 8, 2007
SOLEXA, INC.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

0-22570

(Commission File
Number)

94-3161073

(IRS Employer
Identification Number)

25861 Industrial Blvd.

Hayward, California 94545

(Address of principal executive offices, including zip code)

(510) 670-9300

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURE

EXHIBITS

EXHIBIT 99.1

Table of Contents

Item 8.01. Other Events.

On January 8, 2007, Solexa, Inc. (Solexa) issued a press release announcing an update on milestones related to its Solexa Genome Analysis System. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

Additional Information

In connection with the proposed merger, Illumina, Inc. (Illumina) has filed with the SEC a Registration Statement on Form S-4 that includes a joint proxy statement of Illumina and Solexa that also constitutes a prospectus of Illumina. Illumina and Solexa have mailed the joint proxy statement/prospectus to their respective stockholders. Investors and security holders are urged to read the joint proxy statement/prospectus regarding the proposed merger because it contains important information. You may obtain a free copy of the joint proxy statement/prospectus and other related documents filed by Illumina and Solexa with the SEC at the SEC's website at www.sec.gov. The joint proxy statement/prospectus and the other documents may also be obtained for free by accessing Illumina's website at www.illumina.com under the tab Investors and then under the heading SEC Filings or by accessing Solexa's website at www.solexa.com under the tab Investors and then under the heading SEC Documents.

Participants in the Solicitation

Illumina and Solexa and their respective directors, executive officers and certain other members of management and employees may be soliciting proxies from stockholders in favor of the merger. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of the stockholders in connection with the proposed merger are set forth in the joint proxy statement/prospectus. You can find information about Illumina's executive officers and directors in Illumina's definitive proxy statement filed with the SEC on April 26, 2006. You can find information about Solexa's executive officers and directors in their definitive proxy statement filed with the SEC on August 31, 2006. You can obtain free copies of these documents by using the contact information provided at Illumina's or Solexa's website.

Item 9.01. Financial Statements and Exhibits.

99.1 Press Release, issued on January 8, 2007, entitled Solexa Genome Analysis System Achieves 1G Performance Milestone.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Solexa, Inc.

Dated: January 8, 2007

By: /s/ Linda M. Rubinstein
Linda M. Rubinstein
Vice President and Chief Financial
Officer

Table of Contents

EXHIBITS

- 99.1 Press Release, issued on January 8, 2007, entitled Solexa Genome Analysis System Achieves 1G Performance Milestone.